Wed, September 5, 2012
Tue, September 4, 2012
Mon, September 3, 2012
Sun, September 2, 2012
Sat, September 1, 2012
Fri, August 31, 2012
Thu, August 30, 2012
Wed, August 29, 2012
Tue, August 28, 2012
Mon, August 27, 2012
Sun, August 26, 2012
Sat, August 25, 2012
Fri, August 24, 2012
Thu, August 23, 2012
Wed, August 22, 2012
[ Wed, Aug 22nd 2012 ] - Market Wire
Inergetics Shareholder Update
Tue, August 21, 2012

Targacept to Present at the Stifel Nicolaus 2012 Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. -stifel-nicolaus-2012-healthcare-conference.html
Published in Health and Fitness on Wednesday, August 29th 2012 at 6:02 GMT by Market Wire   Print publication without navigation


WINSTON-SALEM, N.C.--([ ])--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that Alan A. Musso, Senior Vice President, Finance and Administration and Chief Financial Officer, is scheduled to present at the Stifel Nicolaus 2012 Healthcare Conference at Four Seasons Hotel Boston on Wednesday, September 5, 2012 at 1:30 p.m. Eastern Time.

The presentation will be webcast and accessible from the Investor Relations page of Targaceptas website, [ www.targacept.com ]. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Investor Calendar section of the Investor Relations page of Targaceptas website for at least two weeks following the event.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR TherapeuticsTM for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targaceptas clinical pipeline includes Phase 2 product candidates representing first-in-class opportunities. Targacept leverages its scientific leadership and proprietary drug discovery platform PentadTM to fuel its pipeline and attract significant collaborations with global pharmaceutical companies. For more information, please visit [ www.targacept.com ].

TARGACEPT
Building Health, Restoring Independence


Publication Contributing Sources